Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The market is bored

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Feb 09, 2021 1:12pm

142 Views

Post# 32514306

RE:RE:RE:The market is bored

There are three tiers in Nasdaq:The Nasdaq Global Select Market®, The Nasdaq Global Market® and The Nasdaq Capital Market®. Obviously, we would like to be in the top one, which requires $4USD initial listing price.

TriumphSpitSix wrote: The discussion below on NASDAQ was pre-RS since we didn't know which of these events would occur first back in Sept. 2020 when I wrote it. Now that we've got a RoW deal in Asia and the price is moving up to a more appropriate level, it's time to move up to the big board, no additional RS needed.

I still think they can uplist using the $2.00/sh criteria. I'd bet anything this is already underway.

TriumphSpitSix wrote: This inactivity is pretty typical between phases. The 8/4 corporate update also indicated reporting progress "over the coming months" so seems we're in a lull for a while.

Just to help get things organized in my head, below are the upcoming catalysts as far as I can tell. Feel free to correct or add to these:

1. IND submission- Imminent?

2. IND "approval" - 30 days after submission (unless the FDA objects) it becomes effective and trial can proceed. I.e., we may not receive an express "approval" for the IND to start Phase III.

3. EO Ph2 meeting with FDA- "Prior to the start of the first Phase III trial"

4. Start of the first Phase III trial- "[N]ext spring" (late-March to May-ish?)

5. RoW licensing- Potential announcements anytime.

6. Announcement of "brand name" for OPX- Also anytime?

7. Report of preclinical studies for ATB-352- Also anytime?

8 NASDAQ uplisting- Hopefully after a nice pop from some of the above events since it will involve a reverse split. We would need 15:1 or 20:1 to do it now and that would not go over well with investors. Best to get us back to $.55 - $.60 (or higher) and do a 10:1 (or less.)

That's all I got!

woundedknee wrote:
Markets sometime gets bored with a stock like ATE, because it knows that the real deal is some time away and so the holders of the stock go elsewhere in the interim thinking they have time to get back in when the real deal takes place. Some stay and some go. Some win, because they stay, and some lose, because they weren't patient. Still long